Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENV-378
- Development stage
- Preclinical
- Lead developer
- Envisagenics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ENV-378 is a preclinical therapeutic candidate developed by Envisagenics for the treatment of Amyotrophic Lateral Sclerosis (ALS). The drug was identified using Envisagenics' proprietary SpliceCore® platform, an AI-driven discovery engine that analyzes large-scale RNA sequencing data to identify disease-specific alternative splicing events. ENV-378 is designed to target and correct these RNA splicing errors, which are a known hallmark of ALS and other neurodegenerative diseases. The program is currently progressing through the early stages of the drug development pipeline, including in silico discovery, experimental validation, and preclinical testing.
Beyond the preview
Go deeper on ENV-378.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENV-378.